Request to Join
has invited you to join this group
Dr. Buckingham is a Professor in the Department of Pediatric Endocrinology at Stanford Medical Center and Stanford Children’s Hospital. His research focuses on continuous glucose monitoring in children and closed-loop (artificial pancreas) systems. He has been active as the principal investigator at Stanford in multiple NIH, JDRF and Helmsley sponsored research studies including DirecNet, TrialNet, the JDRF randomized clinical trial on continuous glucose monitoring, the JDRF closed-loop consortium, and multicenter Bionic Pancreas studies. He is currently doing closed-loop studies with Medtronic Diabetes, Type Zero, the University of Virginia, Insulet, Bigfoot Biomedical, Tandem, Animas, Rensselaer Polytechnic Institute, and Cambridge. His other interests include algorithms for detecting infusion set and sensor failures and to improve infusion set wear duration.
Edward Damiano, PhD, is Professor of Biomedical Engineering at Boston University. Ever since his son, David, developed type 1 diabetes as an infant over 17 years ago, he has set his sights on creating a bionic pancreas that David could take to college. He and his engineering team at BU began conducting experiments testing an early version of their bionic pancreas running on a laptop computer in diabetic pigs in 2005 and then progressed with their clinical collaborators at the Massachusetts General Hospital through in-patient trials in adults and adolescents with type 1 diabetes from 2008–2012. From 2013–2017, his team at BU and clinical collaborators have conducted seven outpatient clinical trials in adults and children with type 1 diabetes testing a mobile version of their bionic pancreas, which ran on an iPhone. He recently co-founded Beta Bionics, Inc., a Massachusetts Public Benefit Corporation, for the purpose of commercializing a fully integrated, wearable, bionic pancreas device that operates independently of a smartphone. Beta Bionics plans to ready this integrated device for clinical testing later this year and then conduct the final clinical trial testing the first commercial version of this device in the second half of next year.
Ahmad Haidar is an assistant professor in the Department of Biomedical Engineering, McGill University, Montreal, Canada. His research lies in applying control theory and Bayesian modeling to solve diabetes physiological and clinical problems, using a highly interdisciplinary bench-to-bedside approach. The development of the artificial pancreas is the current focus of his research.
Roman Hovorka is Director of Research at the Institute of Metabolic Science and Department of Paediatrics at University of Cambridge. He made seminal contributions to diabetes technology including the “Artificial Pancreas”, a device that delivers insulin in glucose responsive fashion. He is Chief Investigator on several trials evaluating the Artificial Pancreas in populations such as young children and newly diagnosed type 1 diabetes. His wider interests include mathematical modelling of glucose control and turnover.
Rich is an endocrinologist and Executive Director of the International Diabetes Center at Park Nicollet. In 2010 he was the ADA’s, President, Medicine & Science. In 2007, he was ADA’s Outstanding Physician Clinician. He serves on the steering committee of the 81 clinic T1D Exchange Clinic Registry. Dr. Bergenstal was Assistant Professor at the University of Chicago, where he received his MD and endocrinology training, before joining the IDC in 1983. He has served as a principal investigator for several NIH grants including, DCCT/EDIC (T1D), ACCORD & GRADE (T2D) and an NIDDK grant evaluating hybrid closed loop technology. Most of his career has centered on the importance of patient-centered team care and glucose pattern recognition. Two areas of recent focus include, standardizing glucose data reports utilizing the Ambulatory Glucose Profile (AGP) and effective strategies for implementing CGM and hybrid closed loop therapy into clinical practice. He teaches with the IDC team nationally and internationally on the importance of developing new models of care focused on achieving value in healthcare. He has been listed in Best Doctors in America since it began in 1992.